Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

By Nikita Chaurasia  | Date: 2021-05-04

Pfizer donates COVID-19 treatment drugs worth USD 70 million to India

Reportedly, American multinational pharmaceutical firm Pfizer Inc. has extended a helping hand to India in the battle against Covid-19, sending drugs worth USD 70 million to the country. The company is also in discussion with the Indian government to initiate an accelerated approval pathway to make its vaccines available for use in India.

Commenting on the move, Albert Bourla, CEO and Chairman at Pfizer, mentioned they are aware of how critical access to vaccines is to end this pandemic. Their vaccine is not registered in India though they had submitted the application months ago, he added.

Last month, the pharmaceutical giant offered the Indian government's immunization program a non-profit price for its COVID-19 vaccine.

A Pfizer spokesperson expressed they are in talks with the government and remain committed to making their vaccine available for use in India. The drugmaker also stated that its top priority is to help governments solely by providing its vaccine to them for their immunization programs.

It is worth noting that after failing to meet the drug regulator's demand for a local safety and immunogenicity review, the company withdrew an application for emergency-use authorization (EUA) of its COVID-19 vaccine in India in February.

However, the government recently renounced the obligation of presenting local bridge trial data upfront for vaccines permitted by the European Medicines Agency (EMA), UK MHRA, USFDA, or those listed with the WHO under Emergency Use Listing. The pharmaceutical firm is now entitled to seek EUA directly from the DCGI (Drugs Controller General of India) to import its COVID-19 vaccine.

The company is deeply concerned about the grave COVID-19 situation in India, and their hearts go out to all Indians, Bourla wrote in an email he posted on his LinkedIn page, sources confirmed.

The company would be sending drugs worth USD 70 million (over Rs 510 crore) to India from its distribution centers in Asia, Europe, and the United States, according to Bourla's email.

Source Credit –

https://www.moneycontrol.com/news/business/pfizer-donates-70-million-worth-covid-19-treatment-drugs-to-india-6848131.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...

PNAS, Straive partner to deliver end-to-end content production services

PNAS, Straive partner to deliver end-to-end content production services

By Nikita Chaurasia

Renowned U.S.-based nonprofit and non-governmental organization, NAS (National Academy of Sciences), has reportedly collaborated with Straive, one of the leading technology-driven solutions providers for Content, EdTech, and Data. With this acquis...

Japan pushes innovations in 'deep tech' sector with solar cell technology

Japan pushes innovations in 'deep tech' sector with solar cell technology

By Nikita Chaurasia

Amid the most promising next-generation solar cell technology innovations, Enecoat Technologies, a provider of materials development services in Japan, is reportedly developing perovskite. Following its completion, the Kyoto-located start-up expec...

GIC to acquire majority shares in opulent Sani/Ikos properties

GIC to acquire majority shares in opulent Sani/Ikos properties

By Nikita Chaurasia

Singapore's sovereign wealth fund, GIC has agreed to pay around $2.2 billion to buy a majority stake in Sani/Ikos Group, a Mediterranean luxury resort operator, marking the largest transaction in the European resort market since the Covid-19 pand...

Excelra, Patcore partner to offer enhanced digital insights to customers

Excelra, Patcore partner to offer enhanced digital insights to customers

By Nikita Chaurasia

Excelra, a data and analytics solutions provider, has recently announced its partnership with Patcore, Inc., to provide better access to its analytics products and scientific data for customers in Japan. For the unversed, Excelra is one of the top...